九典制药
(300705)
| 流通市值：57.28亿 | | | 总市值：77.43亿 |
| 流通股本：3.70亿 | | | 总股本：5.00亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 588,329,341.07 | 443,307,337.44 | 491,018,878.6 | 499,562,027.45 |
| 衍生金融资产 | - | - | 0 | 0 |
| 应收票据及应收账款 | 375,168,414.54 | 400,022,611.08 | 468,105,227.67 | 469,376,494.38 |
| 其中：应收票据 | 42,907,009.96 | 49,519,971.69 | 44,247,585.15 | 39,584,749.79 |
| 应收账款 | 332,261,404.58 | 350,502,639.39 | 423,857,642.52 | 429,791,744.59 |
| 应收款项融资 | 74,191,922.82 | 69,311,119.37 | 51,813,001.06 | 39,265,391.47 |
| 预付款项 | 32,657,441.93 | 36,559,225.52 | 27,281,706.92 | 17,153,140.65 |
| 其他应收款合计 | 7,625,528.44 | 7,461,335.68 | 6,431,296.16 | 4,482,211.41 |
| 其中:应收利息 | - | - | 0 | 0 |
| 应收股利 | - | - | 0 | 0 |
| 存货 | 366,528,565.07 | 367,704,817.24 | 333,214,211.48 | 320,032,659.35 |
| 合同资产 | 0 | 0 | 0 | 0 |
| 一年内到期的非流动资产 | 0 | 0 | 0 | 0 |
| 其他流动资产 | 1,317,374.59 | 16,697,981.75 | 692,283.73 | 12,061,580.3 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,676,547,724.08 | 1,601,774,702.04 | 1,597,576,477.66 | 1,512,734,633.76 |
| 非流动资产: | | | | |
| 债权投资 | - | - | 0 | 0 |
| 其他债权投资 | - | - | 0 | 0 |
| 长期应收款 | - | - | 0 | 0 |
| 长期股权投资 | 32,393,587.7 | 33,418,858.81 | 1,992,141.51 | 0 |
| 其他权益工具投资 | 98,868,311.49 | 88,868,311.49 | 86,405,000 | 86,405,000 |
| 其他非流动金融资产 | - | 0 | 0 | 0 |
| 投资性房地产 | 4,525,936.32 | 3,737,555.89 | 3,554,642.65 | 3,628,100.62 |
| 固定资产 | 1,305,507,312 | 1,273,640,782.29 | 1,165,382,449.64 | 1,165,405,018.43 |
| 在建工程 | 73,654,570.16 | 80,967,584.65 | 79,978,113.67 | 49,735,861.75 |
| 生产性生物资产 | - | 0 | 0 | 0 |
| 油气资产 | - | 0 | 0 | 0 |
| 使用权资产 | 25,761.11 | 51,522.2 | 77,283.29 | 103,044.38 |
| 无形资产 | 110,227,906.48 | 111,576,633.58 | 106,759,278.02 | 86,993,561.35 |
| 开发支出 | 43,497,867.12 | 38,530,308.24 | 30,162,915.78 | 26,676,639.59 |
| 商誉 | 0 | 0 | 0 | 0 |
| 长期待摊费用 | 6,270,108.53 | 4,154,782.83 | 3,997,144.98 | 4,280,208.29 |
| 递延所得税资产 | 55,243,283.28 | 49,515,107.62 | 52,939,233.02 | 51,725,529.03 |
| 其他非流动资产 | 82,192,673.29 | 86,895,083.07 | 111,851,735.31 | 79,819,330.14 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,812,407,317.48 | 1,771,356,530.67 | 1,643,099,937.87 | 1,554,772,293.58 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,488,955,041.56 | 3,373,131,232.71 | 3,240,676,415.53 | 3,067,506,927.34 |
| 流动负债: | | | | |
| 短期借款 | 0 | 0 | 29,028,625 | 36,035,819.44 |
| 交易性金融负债 | 0 | 0 | 0 | 0 |
| 衍生金融负债 | 0 | 0 | 0 | 0 |
| 应付票据及应付账款 | 103,834,368.44 | 150,719,240.32 | 150,143,858.93 | 155,050,609.02 |
| 其中：应付票据 | 0 | 24,333,279.55 | 31,728,178.55 | 7,394,899 |
| 应付账款 | 103,834,368.44 | 126,385,960.77 | 118,415,680.38 | 147,655,710.02 |
| 预收款项 | 0 | 0 | 0 | 0 |
| 合同负债 | 35,334,484.99 | 30,420,319.47 | 29,088,694.12 | 31,585,346.32 |
| 应付职工薪酬 | 28,636,353.34 | 60,422,881.56 | 31,636,138.56 | 31,797,968.27 |
| 应交税费 | 24,855,577.25 | 26,778,297.66 | 34,851,746.42 | 19,600,398.26 |
| 其他应付款合计 | 68,892,740.07 | 81,282,234.46 | 62,120,516.46 | 64,153,989.19 |
| 其中:应付利息 | - | - | 0 | 0 |
| 应付股利 | - | - | 0 | 0 |
| 一年内到期的非流动负债 | 10,190,334.06 | 8,943,887.51 | 6,136,267.33 | 10,793,666.72 |
| 其他流动负债 | 23,216,224.22 | 33,296,674.81 | 34,726,851.86 | 30,429,871.21 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 294,960,082.37 | 391,863,535.79 | 377,732,698.68 | 379,447,668.43 |
| 非流动负债: | | | | |
| 长期借款 | 183,696,080 | 127,913,000 | 88,000,000 | 81,889,541.15 |
| 应付债券 | 168,147,021.55 | 165,855,235.15 | 244,179,249.14 | 277,550,306.33 |
| 优先股 | - | - | 0 | 0 |
| 永续债 | - | - | 0 | 0 |
| 租赁负债 | 0 | 0 | 0 | 0 |
| 长期应付款 | - | - | 0 | 0 |
| 长期应付职工薪酬 | - | - | 0 | 0 |
| 预计负债 | - | - | 0 | 0 |
| 递延收益 | 188,099,341.31 | 155,952,458.72 | 143,184,354.82 | 145,639,380.91 |
| 递延所得税负债 | 4,690,275.77 | 4,817,142.19 | 4,576,148.92 | 4,703,345.12 |
| 其他非流动负债 | - | - | 0 | 0 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 544,632,718.63 | 454,537,836.06 | 479,939,752.88 | 509,782,573.51 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 839,592,801 | 846,401,371.85 | 857,672,451.56 | 889,230,241.94 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 496,196,815 | 496,194,320 | 489,629,635 | 486,526,829 |
| 其他权益工具 | 48,452,486.05 | 48,461,522.91 | 72,207,279.12 | 83,430,671.83 |
| 资本公积 | 565,117,331.42 | 563,546,259.47 | 467,077,986.66 | 419,704,332.79 |
| 减:库存股 | 4,995,170.26 | 0 | 0 | 0 |
| 其他综合收益 | 4,882,664.77 | 4,882,664.77 | 2,788,850 | 2,788,850 |
| 专项储备 | 295,936.61 | 8,626.26 | 306,138.03 | 436,219.8 |
| 盈余公积 | 165,874,571.12 | 165,874,571.12 | 124,462,975.51 | 124,462,975.51 |
| 未分配利润 | 1,373,537,605.85 | 1,247,761,896.33 | 1,226,531,099.65 | 1,060,926,806.47 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,649,362,240.56 | 2,526,729,860.86 | 2,383,003,963.97 | 2,178,276,685.4 |
| 少数股东权益 | 0 | 0 | 0 | 0 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,649,362,240.56 | 2,526,729,860.86 | 2,383,003,963.97 | 2,178,276,685.4 |
| 负债和股东权益合计 | 3,488,955,041.56 | 3,373,131,232.71 | 3,240,676,415.53 | 3,067,506,927.34 |
| 公告日期 | 2025-04-24 | 2025-04-24 | 2024-10-29 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |